UOC
AUTL

UBS O'Connor’s Autolus Therapeutics AUTL Stock Holding History

UBS O'Connor’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-565,000
Closed -$1.29M – 293
2025
Q2 		$1.29M Buy
+565,000
New +$934K 0.04% 184
2024
Q2 		– Sell
-155,857
Closed -$994K – 546
2024
Q1 		$994K Sell
155,857
-382,909
-71% -$2.39M 0.03% 277
2023
Q4 		$3.47M Sell
538,766
-47,153
-8% -$180K 0.11% 103
2023
Q3 		$1.37M Buy
585,919
+55,000
+10% +$157K 0.02% 295
2023
Q2 		$1.26M Sell
530,919
-226,089
-30% -$536K 0.03% 360
2023
Q1 		$1.39M Buy
+757,008
New +$1.48M 0.03% 376
2022
Q4 		– Sell
-584,406
Closed -$1.25M – 41
2022
Q3 		$1.25M Buy
584,406
+160
+0% +$474 0.01% 720
2022
Q2 		$1.65M Buy
+584,246
New +$1.78M 0.02% 689

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's AUTL Position: Q3 2025 in Review

UBS O'Connor sold out of Autolus Therapeutics (AUTL) in Q3 2025, closing a stake of 565,000 shares — an estimated $1.29M sold.

UBS O'Connor first reported a position in AUTL in Q2 2022 and held it in 8 quarters. The position peaked at $3.47M in Q4 2023. 96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • UBS O'Connor reported no remaining Autolus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 565,000 Autolus Therapeutics shares in Q3 2025, an estimated $1.29M.
  • UBS O'Connor first reported a position in Autolus Therapeutics in Q2 2022 and held it in 8 quarters.
  • UBS O'Connor's Autolus Therapeutics position peaked at $3.47M in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.